questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Chimiokines
Chimiokines CC
Protéines chimioattractives monocytaires
Chimiokine CCL2
Chimiokine CCL2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Chimiokines
CCL2
Tests de laboratoire
Inflammation
CCL2
Protéines C-réactives
Biomarqueurs
Maladies auto-immunes
CCL2
Maladies cardiovasculaires
Inflammation
CCL2
Liquide céphalorachidien
Inflammation
CCL2
Symptômes
5
Symptômes
Inflammation
CCL2
Sclérose en plaques
Symptômes neurologiques
CCL2
Système immunitaire
Monocytes
CCL2
Douleur
Inflammation
CCL2
Prévention
5
Mode de vie sain
CCL2
Prévention
Alimentation
Antioxydants
CCL2
Sommeil
Inflammation
CCL2
Traitements
5
Inhibiteurs
Maladies inflammatoires
CCL2
Thérapies anticancéreuses
CCL2
Inflammation
Anti-inflammatoires
CCL2
Inflammation
Plantes médicinales
CCL2
Traitements naturels
Corticostéroïdes
CCL2
Inflammation
Complications
5
Complications
Maladies cardiovasculaires
CCL2
Maladies neurodégénératives
Alzheimer
CCL2
Diabète
Inflammation
CCL2
Infections
Inflammation
CCL2
Troubles auto-immuns
Polyarthrite
CCL2
Facteurs de risque
5
Infections chroniques
CCL2
Inflammation
Régime alimentaire
Graisses saturées
CCL2
Manque d'exercice
Inflammation
CCL2
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chimiokine CCL2 : Questions médicales les plus fréquentes",
"headline": "Chimiokine CCL2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chimiokine CCL2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chimiokine CCL2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines chimioattractives monocytaires",
"url": "https://questionsmedicales.fr/mesh/D018945",
"about": {
"@type": "MedicalCondition",
"name": "Protéines chimioattractives monocytaires",
"code": {
"@type": "MedicalCode",
"code": "D018945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.110.990"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CCL2",
"alternateName": "Chemokine CCL2",
"code": {
"@type": "MedicalCode",
"code": "D018932",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nidhi Joshi",
"url": "https://questionsmedicales.fr/author/Nidhi%20Joshi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India."
}
},
{
"@type": "Person",
"name": "Krishna Mohan Poluri",
"url": "https://questionsmedicales.fr/author/Krishna%20Mohan%20Poluri",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in."
}
},
{
"@type": "Person",
"name": "Nupur Nagar",
"url": "https://questionsmedicales.fr/author/Nupur%20Nagar",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India."
}
},
{
"@type": "Person",
"name": "Élora Midavaine",
"url": "https://questionsmedicales.fr/author/%C3%89lora%20Midavaine",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca."
}
},
{
"@type": "Person",
"name": "Philippe Sarret",
"url": "https://questionsmedicales.fr/author/Philippe%20Sarret",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36546488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4102/phcfm.v14i1.3736"
}
},
{
"@type": "ScholarlyArticle",
"name": "Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37850783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.23750/abm.v94i5.13751"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.",
"datePublished": "2022-08-12",
"url": "https://questionsmedicales.fr/article/35964881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvir.2022.08.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate organogenesis.",
"datePublished": "2022-06-21",
"url": "https://questionsmedicales.fr/article/35726824",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1242/dev.200394"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36974872",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i3.4613"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Chimiokines",
"item": "https://questionsmedicales.fr/mesh/D018925"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chimiokines CC",
"item": "https://questionsmedicales.fr/mesh/D019742"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines chimioattractives monocytaires",
"item": "https://questionsmedicales.fr/mesh/D018945"
},
{
"@type": "ListItem",
"position": 8,
"name": "Chimiokine CCL2",
"item": "https://questionsmedicales.fr/mesh/D018932"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chimiokine CCL2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chimiokine CCL2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chimiokine CCL2",
"description": "Comment mesurer les niveaux de CCL2 ?\nQuels tests sont utilisés pour évaluer l'inflammation ?\nCCL2 est-il un biomarqueur de maladies ?\nComment CCL2 est-il lié à la maladie cardiovasculaire ?\nPeut-on détecter CCL2 dans le liquide céphalorachidien ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostate#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chimiokine CCL2",
"description": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?\nCCL2 est-il lié à des symptômes neurologiques ?\nComment CCL2 affecte-t-il le système immunitaire ?\nDes niveaux de CCL2 peuvent-ils causer de la douleur ?\nCCL2 est-il impliqué dans des maladies respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostate#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chimiokine CCL2",
"description": "Comment réduire les niveaux de CCL2 ?\nLe stress influence-t-il CCL2 ?\nY a-t-il des aliments qui réduisent CCL2 ?\nL'exercice physique affecte-t-il CCL2 ?\nLa qualité du sommeil influence-t-elle CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostate#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chimiokine CCL2",
"description": "Quels traitements ciblent CCL2 ?\nCCL2 peut-il être une cible pour des thérapies anticancéreuses ?\nComment les anti-inflammatoires affectent-ils CCL2 ?\nY a-t-il des traitements naturels pour CCL2 ?\nLes corticostéroïdes influencent-ils CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostate#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chimiokine CCL2",
"description": "Quelles complications sont liées à CCL2 ?\nCCL2 est-il impliqué dans des maladies neurodégénératives ?\nComment CCL2 affecte-t-il le diabète ?\nY a-t-il des risques d'infection liés à CCL2 ?\nCCL2 est-il lié à des troubles auto-immuns ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostate#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chimiokine CCL2",
"description": "Quels facteurs augmentent CCL2 ?\nL'âge influence-t-il les niveaux de CCL2 ?\nLes infections chroniques affectent-elles CCL2 ?\nLe régime alimentaire influence-t-il CCL2 ?\nLe manque d'exercice est-il un facteur de risque pour CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prostate#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer les niveaux de CCL2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de CCL2 peuvent être mesurés par des tests ELISA dans le sérum ou les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'inflammation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la CRP et la mesure de CCL2 aident à évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "CCL2 est-il un biomarqueur de maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est un biomarqueur potentiel pour des maladies inflammatoires et auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment CCL2 est-il lié à la maladie cardiovasculaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 sont associés à l'inflammation dans les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on détecter CCL2 dans le liquide céphalorachidien ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 peut être détecté dans le liquide céphalorachidien, indiquant une inflammation neurologique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent entraîner des symptômes d'inflammation comme douleur et fatigue."
}
},
{
"@type": "Question",
"name": "CCL2 est-il lié à des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est impliqué dans des symptômes neurologiques dans des maladies comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Comment CCL2 affecte-t-il le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "CCL2 attire les monocytes et les lymphocytes, influençant la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Des niveaux de CCL2 peuvent-ils causer de la douleur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 peut contribuer à la douleur en favorisant l'inflammation dans les tissus."
}
},
{
"@type": "Question",
"name": "CCL2 est-il impliqué dans des maladies respiratoires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est associé à des maladies respiratoires comme l'asthme et la BPCO."
}
},
{
"@type": "Question",
"name": "Comment réduire les niveaux de CCL2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il CCL2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter les niveaux de CCL2 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des aliments qui réduisent CCL2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des aliments riches en antioxydants, comme les baies, peuvent aider à réduire CCL2."
}
},
{
"@type": "Question",
"name": "L'exercice physique affecte-t-il CCL2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut diminuer les niveaux de CCL2 et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "La qualité du sommeil influence-t-elle CCL2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un sommeil de qualité peut réduire l'inflammation et les niveaux de CCL2 dans le corps."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CCL2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de CCL2 sont en développement pour traiter des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "CCL2 peut-il être une cible pour des thérapies anticancéreuses ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, cibler CCL2 pourrait aider à réduire l'infiltration tumorale et l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les anti-inflammatoires affectent-ils CCL2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires peuvent réduire les niveaux de CCL2 et atténuer l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour CCL2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent moduler les niveaux de CCL2, mais des études sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes influencent-ils CCL2 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'expression de CCL2 dans les tissus inflammés."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à CCL2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent entraîner des complications dans les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "CCL2 est-il impliqué dans des maladies neurodégénératives ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est associé à des complications dans des maladies comme Alzheimer et Parkinson."
}
},
{
"@type": "Question",
"name": "Comment CCL2 affecte-t-il le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "CCL2 peut contribuer à l'inflammation et aux complications associées au diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'infection liés à CCL2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent augmenter le risque d'infections en favorisant l'inflammation."
}
},
{
"@type": "Question",
"name": "CCL2 est-il lié à des troubles auto-immuns ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est impliqué dans des complications de troubles auto-immuns comme la polyarthrite."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent CCL2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'obésité et le stress sont des facteurs de risque augmentant CCL2."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de CCL2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de CCL2 tendent à augmenter avec l'âge, contribuant à l'inflammation."
}
},
{
"@type": "Question",
"name": "Les infections chroniques affectent-elles CCL2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques peuvent augmenter les niveaux de CCL2 dans le corps."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire influence-t-il CCL2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un régime riche en graisses saturées peut augmenter les niveaux de CCL2 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque pour CCL2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le manque d'exercice peut contribuer à des niveaux élevés de CCL2 et à l'inflammation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 20/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Publications dans "Chimiokine CCL2" :
4 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in.
Publications dans "Chimiokine CCL2" :
3 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Centre of Biomedical Research, SGPGIMS Campus, Lucknow 226014, Uttar Pradesh, India.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Affiliated Hospital of Nantong University, 226001, Nantong, Jiangsu Province, China.
School of Medicine, Nantong University, 226001, Nantong, Jiangsu Province, China.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy.
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. jgozdowska@wum.edu.pl
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
College of Medicine and Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
College of Medicine and Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Publications dans "Chimiokine CCL2" :
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...
To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla...
A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a...
Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24...
PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...
Prostate organogenesis begins during embryonic development and continues through puberty when the prostate becomes an important exocrine gland of the male reproductive system. The specification and gr...
Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le...
This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ...
A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu...
BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...
Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin...
A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch...
Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ...
Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...
The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV)....
The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr...
In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/...
Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...
Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...
This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population....
A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an...
140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand...
The PHI test improves PCa detection compared to tPSA in our population....
We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy....
This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf...
A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta...
Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...